ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,287.30
0.07%
Dow Jones
44,910.65
0.42%
Gold vs US Dollar
2,649.87
0.00%
Brent Oil
71.98
0.00%
Bitcoin
96,402.24
-0.03%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX

  6. Can Fite BioPharma Ltd (CANF) Share Price

CANF Can Fite BioPharma Ltd

2.20
0.10 (4.76%)
29 Nov 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Can Fite BioPharma Ltd AMEX:CANF American Stock Exchange Common Stock  ADS each representing three hundred Ordinary Shares
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.10 4.76 2.20 0.00 0.00 2.2799 2.14 2.2 39,344 22:00:00   
*quotes are delayed by at least 20 minutes
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations 743k -7.63M - N/A 11.7M
 Type  Size  Price  Time  Units 
 13 100 2.20 22:00:00 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore CANF News
14/11/202421:48EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
11/11/202412:00GLOBECan-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
04/11/202412:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
04/11/202412:08GLOBECan-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
18/10/202413:23EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
18/10/202413:06GLOBESignificant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
09/10/202411:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Period
Draw mode
Data Downloads for CANF

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Can Fite BioPharma Ltd Articles

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 50%* for Gold Trader

1 year 30%, 2 years 40% and *3 years 50%

*Across 3 years £3655.44 only £1827.72